ArticleClinical pharmacology and therapeutics2025
Exploring the Association Between Intra-Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients.
Article in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pazopanib is an oral tyrosine kinase inhibitor used in patients with either metastatic renal cell carcinoma or soft tissue sarcoma. Pazopanib has a high interindividual variability in pharmacokinetics and pharmacodynamics and a well-established exposure-response relationship. Therefore, therapeutic drug monitoring is recommended to improve the efficacy-toxicity balance. Intra-patient variability in pazopanib pharmacokinetics is moderate with a mean of 24.7%. In other fields, such as transplantation medicine, a high intra-patient variability of immunosuppressive drugs has previously been associated with worse outcomes. Whether this also applies to therapeutic modalities in oncology is unknown. The aim of this study was to explore the relationship between pazopanib intra-patient variability and clinical outcomes. Data from patients diagnosed with either metastatic renal cell carcinoma or soft tissue sarcoma treated with pazopanib guided by routine therapeutic drug monitoring with at least three available pazopanib trough concentrations were retrieved. Non-dose corrected estimated trough concentrations were used to calculate intra-patient variability. Among 144 patients, median intra-patient variability was 30.2%. The high intra-patient variability group (intra-patient variability > 30.2%) was at risk for worse progression-free survival (HR 1.42; 95% CI 0.85-2.35) and overall survival (HR 2.17; 95% CI 1.10-4.29) in patients with renal cell carcinoma. No association between a high intra-patient variability and clinical outcomes for patients with soft tissue sarcoma could be established. Our results show that high intra-patient variability is associated with poorer treatment outcomes. A high intra-patient variability urges the treating clinician to address therapy adherence, drug-drug and food-drug interactions, and improve chances for optimal treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.